Dogwood (DWTX) Therapeutics “announced top line data from the recently completed BHC IMC-2 Long-COVID study. The study was conducted via an investigator-initiated, investigational research grant ...
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo ...
ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat ...
(RTTNews) - Virios Therapeutics, Inc. (VIRI) announced receipt of the FDA feedback on requirements for advancing IMC-2, or a combination of valacyclovir + celecoxib, as a treatment for the fatigue, ...
ATLANTA--(BUSINESS WIRE)--$VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination ...
ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company advancing new medicines to treat pain and ...
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 - - Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, ...
The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback